Kyowa Kirin Halts Rocatinlimab Trials Due to Safety Concerns – Kaposi’s Sarcoma Cases Reported

Rocatinlimab Trials Halted Amid Safety Concerns

Kyowa Kirin has announced the discontinuation of all clinical trials evaluating rocatinlimab, an investigational antibody targeting the OX40 receptor, following a safety review that revealed emerging concerns regarding malignancies. The decision impacts trials assessing the drug’s potential in moderate-to-severe atopic dermatitis, asthma, and prurigo nodularis. This development underscores the complex challenges inherent in developing immunomodulatory therapies, even after promising early results.

The pause stems from the identification of one new confirmed case and one suspected case of Kaposi’s sarcoma, in addition to a previously reported case. Kaposi’s sarcoma is a cancer that develops from the cells that line lymph or blood vessels. The National Cancer Institute describes it as a relatively rare cancer, but one that can be more common in people with weakened immune systems. Kyowa Kirin believes these cases suggest a potential link between OX40 pathway modulation and malignancy risk, though the precise nature of that link remains under investigation.

OX40 and Immunotherapy: A Promising Target, Careful Evaluation

Rocatinlimab works by targeting OX40, a receptor found on T cells – key players in the immune system. By activating OX40, the drug aims to enhance the immune response, particularly in conditions driven by immune dysregulation, such as atopic dermatitis. The OX40 pathway is involved in T-cell activation and memory, making it an attractive target for therapies seeking to modulate the immune system. However, altering immune pathways carries inherent risks, as evidenced by this recent development.

Although overall malignancy rates across the rocatinlimab clinical program remain within expected background levels, the specific characteristics of the observed cases prompted the company to prioritize patient safety. “This is deeply disappointing news, as we had hoped to bring a safe and effective treatment to patients,” said Abdul Mullick, PhD, president and CEO of Kyowa Kirin, in a press release. “Rocatinlimab has demonstrated durable and clinically meaningful efficacy in moderate-to-severe atopic dermatitis in the ROCKET program. However, the safety profile has evolved, and as patient safety remains our highest priority, we have taken this decisive and cautious step.”

Recent Trial Data and Prior Optimism

The decision to halt trials comes after promising data emerged from phase 3 studies, ROCKET-IGNITE and ROCKET-HORIZON, which demonstrated improvements in moderate-to-severe atopic dermatitis. Healio previously reported on these findings, highlighting the potential of rocatinlimab to modify the disease course. These studies established the OX40 receptor as a validated therapeutic target, fueling optimism within the dermatology community. Reported treatment-emergent adverse events in those trials were generally similar between the rocatinlimab and placebo groups, with common side effects including fever, chills, and mouth sores.

What Does This Mean for Patients and Future Research?

The immediate impact of this decision is the termination of ongoing clinical trials. Kyowa Kirin and its partner, Amgen, are notifying investigators and regulatory authorities, and will conduct follow-up safety assessments for current trial participants before formally closing the studies. Patients currently enrolled in these trials should consult with their healthcare providers for guidance on continued care.

While the halt of rocatinlimab development is a setback, Kyowa Kirin emphasizes that the knowledge gained from the program will inform future research into OX40 pathway modulation. The company plans a comprehensive analysis of the full dataset to better understand the observed safety signals and refine strategies for developing safer immunomodulatory therapies. This process will involve a detailed investigation into potential viral or immune-related factors contributing to the observed malignancies.

Commercialization Partnership Dissolved

This safety review and subsequent trial termination follow a January announcement that Kyowa Kirin and Amgen were ending their commercialization partnership for rocatinlimab, citing strategic portfolio prioritization. At the time, Kyowa Kirin had anticipated submitting a regulatory application to the FDA in the first half of 2026, a plan now abandoned.

The Broader Context of Immunotherapy Safety

The rocatinlimab situation highlights the inherent complexities of immunotherapy, a rapidly evolving field with the potential to revolutionize the treatment of various diseases. While immunotherapies have demonstrated remarkable efficacy in certain cancers and autoimmune conditions, they also carry the risk of immune-related adverse events, including inflammation and, in rare cases, malignancies. Careful monitoring and rigorous safety evaluation are crucial throughout the development and clinical apply of these therapies.

Mona Shahriari, MD, FAAD, Associate Clinical Professor of Dermatology at Yale University School of Medicine, commented on the implications of this development. “OX40/OX40L targeting has been explored as an upstream strategy in atopic dermatitis with the aim of modulating sustained T-cell activation and immune memory. The discontinuation of rocatinlimab underscores the importance of rigorous, long-term safety evaluation — and reinforces the need to balance mechanistic promise with careful safety assessment — when developing therapies that alter costimulatory signaling. These findings add to our understanding of how best to approach immune recalibration in a complex, heterogeneous disease like AD.”

Next Steps: Researchers will now focus on a thorough analysis of the clinical trial data to identify potential risk factors and refine understanding of the relationship between OX40 modulation and malignancy. Regulatory agencies will review the findings and may issue updated guidance on the development of OX40-targeted therapies. Continued vigilance and robust safety monitoring will be essential as research in this area progresses.